Multiple Myeloma

Saad Usmani, MD, shares his excitement for additional clinical trial data in multiple myeloma presented at the ASH 2021 annual meeting.

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.

Insight on the BELLINI study, which added venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.

Closing out his discussion on newly diagnosed multiple myeloma, Saad Usmani, MD, considers the approval and use of subcutaneous daratumumab.

In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy.

Expert perspective on results from the MASTER study analyzing daratumumab in combination with KRd in transplant-eligible newly diagnosed multiple myeloma.

Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly diagnosed multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, discusses emerging treatment strategies in late relapsed multiple myeloma.

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma.

Ola Landgren, MD, PhD, reviews the results and clinical implications of the IKEMA study for patients with relapsed/refractory multiple myeloma.

Katja Weisel, MD, leads a review of the study design and updated efficacy and safety results of the phase 3 CANDOR study for patients with relapsed/refractory multiple myeloma.

Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

Ajai Chari, MD, reviews the takeaways from the PLEIADES trial and its comparability with the CANDOR trial, and how a subcutaneous formulation of a daratumumab combination became a pivotal player in the treatment enhancement for patients with relapsed or refractory multiple myeloma.

Ola Landgren, MD, PhD; Sagar Lonial, MD; and Joshua Richter, MD, review current available treatment options and factors to consider when selecting therapy for patients with multiple myeloma who experience a first relapse.

Katja Weisel, MD, and Joshua Richter, MD, define biochemical vs clinical relapses in multiple myeloma and share recommendations for initiating treatment at either stage.

The Japanese Ministry of Health, Labour, and Welfare has approved idecabtagene vicleucel for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 3 therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and have progressed on their last therapy or relapsed following their last therapy.

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Certain patient and disease characteristics must be considered to select the optimal treatment approach for difficult-to-treat patients with relapsed or refractory multiple myeloma.

Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.

When treating cancers that are considered generally incurable, such as multiple myeloma, one of the paradigms in oncology is to deliver the most effective therapies upfront to maximize the chances of prolonging remission.

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.